Ciliary neurotrophic factor (CNTF) has originally been identified as a potent survival factor for a variety of neuronal cell types in vitro [l}, in particular, spinal motoneurons of embryonic chick and rat [2-4}. CNTF prevents the degeneration of motoneurons in vivo during embryonic development when applied onto the chorioallantoic membrane of developing chick [5}, and in lesion experiments when delivered to the proximal stump of a lesioned facial nerve of newborn rats [6}.
Transgenic mice lacking functional CNTF gene expression develop normally until birth but develop progressive atrophic and degenerative changes in motoneurons after the first postnatal weeks [7}. This suggests that the physiological function of CNTF might be confined to the maintenance of neuronal function in the adult rather than in survival and early differentiation of neuronal cells during development. The finding that systemically delivered CNTF is capable of preventing the degeneration and functional loss of motoneurons in the homozygous progressive motor neuronopathy (pmn) mouse mutant [8}, an a~lmal model for human spinal motoneuron disease, has raised hopes that this factor might be useful in the treatment of human degenerative disorders such as amyotrophic lateral sclerosis (ALS) [9}' However, little is known so far about the pharmacokinetics and the side effects of CNTF after systemic injection, information that is a prerequisite for potential clinical use of this compound in humans.
Endogenous expression of CNTF is found in myelinating Schwann cells of peripheral nerves as well as in a subpopulation of astrocytes, in particular, in the optic nerve and the olfactory bulb of adult rats [lO}. CNTF does not share any sequence homology or similarity in biochemical properties with the members of the nerve growth factor (NGF) gene family of neurotrophic factors [ll}. Predictions of the protein structure of CNTF have suggested that CNTF has a helical framework similar to leukemia inhibitory factor (LIF), oncostatin M, interleukin-6 (IL-6), and granulocyte colony-stimulating factor (G-CSF) [12}. However, CNTF differs from these molecules in that it is a cytosolic molecule that does not possess a signal peptide for secretion through the conventional endoplasmic reticulum-golgi apparatus pathway. Moreover, CNTF does not appear to be glycosylated and lacks cysteine bridges, indicating that the physicochemical properties Of CNTF could significantly differ from those of its structural relatives [11-16}. Therefore, pharmacokinetic data obtained in vivo for recombinant human (rh) factors like rhIL-6 [I7} and rhG-CSF [18} and for murine LIF [19} might not necessarily be pertinent to CNTF.
The membrane-associated CNTF receptor complex appears to be composed of at least three subunits, the CNTF receptor a (CNTFRa), the glycoprotein gp130, and the LIF receptor f3 (LIFRf3) (for reviews, see [20-22}) . The structure of CNTFRa has been found to be unrelated to the receptors for NGF and related neurotrophins (23} but homologous to the low-affinity IL-6 receptor a (IL-6Ra) [20-22, 24} . The expression of CNTFRa has been described to be mainly restricted to the nervous system and skeletal muscle [24, 25} . It was concluded from these findings that actions of CNTF after systemic administration might be restricted to these tissues. In this study we have examined the pharmacokinetics and some side effects of systemically administered CNTF in the rat.
Materials and Methods Animals
Adult male Wistar rats weighing 150 to 200 gm were used for all experiments. The rats were obtained from the breeding facilities of the Max-Planck-Institute of Biochemistry, where they are kept under specific pathogen-free conditions. Rats were supplied with food and tap water ad libitum throughout the course of the experiments. Experiments were performed in accordance with Bavarian state legislation.
Radioiodination of C-terminal-modified CNTF
Recombinant rat CNTF contains only four tyrosine residues [11} and could not be iodinated to high specific radioactivity without using large amounts of 1251-Na (P. Phelan, unpublished results). Therefore, a modified recombinant rat CNTF with three additional C-terminal tyrosine residues, here denoted CNTFY, was designed by adding three codons for tyrosine to the 3' end of the coding region of the cDNA for rat CNTF (K. Stockli, unpublished results), expressed in E. coli as described [26] and used for iodination. Both CNTF and CNTFY were purified from transfected E. coli using a modification of the method described by Masiakowski and colleagues [26}, in which the chromatographic purification of the protein on DEAE-cellulose was replaced by a single reverse-phase, high-pressure liquid chromatography (HPLC) step on a preparative column (Vydac C4). Both CNTF and CNTFY eluted as a single peak at 50 to 55 % acetonitrile with 0.1 % trifluoroacetic acid, and migrated as a single band on a sodium dodecyl sulfate (SDS) containing polyacrylamide gel under reducing conditions (data not shown). The peak fractions, eluted from HPLC columns, were stored at -70°C after addition of n-octyl-(3-o-glucopyranoside (final concentration of 0.1 % ). Protein concentration was determined by amino acid analysis prior to use. Radioiodination was performed by addition of lactoperoxidase (5.4 x 10 -13 mol), H 2 0 2 (2.3 x 10-9 mol), and 0.3 mCi of 125I_Na to 1 fLg of CNTFY (4.4 x 10 -11 mol) diluted in 50 fLl of 35 mM potassium acetate at pH 5. This mixture was incubated for 15 minutes at room temperature. After a further IS-minute incubation step with a second addition of H 2 0 2 (2.3 x 10-9 mol), the specific radioactivity of 125 1_
CNTFY was determined by precipitating an aliquot of the reaction in 20% trichloroacetic acid (TCA) containing 0.25 % bovine serum albumin (BSA) and 0.3 % Nal, and measuring 
Bioassay
The chick ciliary neuron survival assay was performed as described [27}. Surviving neurons were counted after 24 hours in culture, and the factor concentration that supported halfmaximal survival of the cultured neurons was found to be 50,62, and 70 pg/ml for CNTF, CNTFY, and 125I_CNTFY, respectively (Fig 1) . Taking into account the variability of the assay, the biological activity of all three molecules was indistinguishable.
Detection of Intravenously Injected 125I_CNTFY
Clearance and tissue distribution of CNTF was determined after injection of 0.1 or 0.5 fLg of m I-CNTFY in 300 fLlof phosphate-buffered saline (PBS) into the tail vein of etheranesthetized adult male Wistar rats (150-200 gm). At different time points after injection, the rats were killed by ether overdose and blood was obtained by heart puncture. Organs were removed after perfusion with 100 ml ofPBS containing 1,000 units of heparin to remove vascular-from tissue-bound 125I-CNTFY. We chose this technique because no vascular marker was available showing identical distribution in the circulation as CNTF. The weight of wet tissue of the prepared organs was measured and the radioactivity was counted for 10 minutes in a gamma counter. Aliquots of the tissues were homogenized and precipitated in 20% TCA to determine the extent of degradation of 125I_CNTFY.
Autoradiography of Polyacrylamide Gels
Discontinuous polyacrylamide gel electrophoresis (PAGE) [28} was used for further analysis of blood and tissues collected at different times after intravenous (i. v.) injection of 125I_CNTFY. For SDS-P AGE under reducing conditions the separations were performed for serum on 4 to 15% gradient gels, for liver extracts on 10 to 20% gradient gels, and for liver cell membrane proteins cross-linked to 125I_CNTFY on 6.5 % gels. Serum was also separated by PAGE at pH 9.5 under nondenaturating conditions on 4 to 15 % gradient gels prepared without SDS. The gels were dried and exposed to x-ray films (Fuji, RX) at -70°C with intensifying screens. Band intensities were determined by scanning the autoradiograms with a densitometer (Molecular Dynamics).
Autoradiography of Tissue Sections
At various time periods after i.v. injection of 0.1 /-Lg 0.94 X 10 7 cpm) of 125I-CNTFY, rats were perfused with 0.01% lidocaine in PBS and subsequently with 4% paraformaldehyde in PBS. Tissues were dissected, postfixed for 2 hours, dehydrated by several washing steps with 20% sucrose in PBS, and frozen sections (7 /-Lm) were prepared. Finally, these sections were dipped in LM-l emulsion (Amersham) and developed after at least 3 days according to manufacturer's directions. After washing, the slides were stained with hematoxylin and eosin.
Cross-Linking of 125I_CNTFY In Situ
Five minutes after i.v. injection of 0.5 /-Lg (7 .1 X 10 7 cpm) of 125I_CNTFY, rats were killed by ether overdose and 10 ml of KRH containing the cross-linking agent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) at a concentration of 300 mM was injected into the liver via the portal vein. After 20 minutes of incubation on ice,S ml of 1 M glycine in PBS was injected via the portal vein to stop the reaction. The liver was removed and minced in homogenization buffer at pH 7.4 containing sucrose (0.25 mM), NaHC0 3 0 mM), MgCl 2 (2 mM), glycine (1 M), phenylmethylsulfonyl fluoride o mM), aprotinin (l.5 /-LM), and leupeptin (2.4 /-LM) with a glass-glass homogenizer by 15 strokes at 500 rpm. Cell membranes were pelleted by centrifuging the homogenate (10 minutes, 1,000 g at 4°C). The pellet was washed once with homogenization buffer and the membranes were further purified by two-polymer phase partitioning as described [29}. The interphase was lysed in Tris-buffered saline at pH 7.4 containing 1 % Nonidet P-40 and 10% glycerol, and insoluble residues were removed by centrifugation for 5 minutes at 12,000 g. The supernatant was separated by SDS-PAGE and analyzed by autoradiography.
Northern Blot Analysis of Acute-Phase Response
Recombinant rat CNTF was lyophilized after dilution in a buffer suitable for i.v. injection in humans (Elomel, Boehringer) containing 0.25 % BSA (Sigma) with a low endotoxin content. When redissolved in pyrogen-free water, the CNTF showed no loss of biological activity (data not shown). CNTF was injected i.v. in a volume of 300 /-LI as described above, and after different time points the liver was removed from the killed rat and chilled in liquid nitrogen. RNA was extracted with guanidinium-thiocyanate and further purified by isopyknic gradient centrifugation in cesium trifluoroacetate [30}. Fifteen micrograms of total RNA were electrophoresed through l.2 % agarose gels containing formaldehyde (2 M) and vacuum-blotted to nylon membranes (Hybond-N, Amersham). Hybridization was performed overnight at 42°C as described [1O} with 5 X 10 6 cpm/ml of a radioactive random prime-labeled cDNA probe for human haptoglobin [31] . Haptoglobin is induced as an acute-phase protein both in human and rat [32}. Rat haptoglobin shows 75% and 82 % amino acid sequence identity with the (X-and f3-subunits of the human haptoglobin allele one gene product (33}; at the cDNA level, the sequence identity for the f3-subunit is approximately 78% [34}. After washing twO times in 2 X saline-sodium citrate (SSC) containing 0.1 % SDS at room temperature and once for 30 minutes in 0.1 X SSC containing 0.5 % SDS at 50°C, the blots were exposed to x-ray films (Fuji, RX) at -70°C with intensifying screens. Band intensities were determined by scanning the auto radiograms with a densitometer (Molecular Dynamics).
Results

Clearance from the Blood of Intravenously Injected 125I_CNTFY
Following i.v. injection of 0.1 f..Lg (1 x 10 7 cpm) of l2'iI-CNTFY, approximately 75% of the radioactivity was removed from the circulation within 10 minutes. The initial half-time of clearance (to .5) of 125I-CNTFY from the blood was 2.9 minutes, while the subsequent decrease of 125I-CNTFY levels in the blood was less rapid (to .5' 4 hr) (Fig 2) . The highest tissue concentrations of 125I_CNTFY 10 minutes after i.v. injection were found in the liver (6.88 ± 0.23 x 10 5 cpm/gm of tissue) (Fig 3a) , indicating that about 70% of the injected radioactiviry has accumulated in this organ (total wet weight of liver, 11 .5 gm). At the same time, the levels of radioactivity in the urine were still very low, and the kidneys contained only about 7% of the injected radioactivity (3.86 ± 0.4 x 10 5 cpm/ gm of wet tissue), confirming that the rapid removal of 125 1_ CNTFY from the circulation within the first 10 minutes occurred via the liver rather than by renal clearance. At 6 hours after i.v. injection, more than 70% of the total amount of injected radioactivity was detectable in the skin. Thus, removal of 125I-CNTFY and its radioactive degradation products by renal clearance "0 seems to play only a minor role in removing the radioactivity from the circulation also during the second slower clearance phase. Indeed, levels of measurable radioactivity in the urine were quite low (0.4 x 10 5 cpm/ 50 f.LI at 10 minutes, 1.7 x 10 5 cpm/ 50 f.LI at 60 minutes, and 0.3 x 10 5 cpm/50 f.L1 at 3 hours after i.v.
injection), suggesting that less than 10% of the injected radioactivity is removed by renal clearance within 3 hours after i.v. injection of 125I_CNTFY.
Binding Proteins for 125I_CNTFY in the Blood
The autoradiograms of serum samples collected within 1 hour after i.v. injection of 0.1 f.Lg (l X 10 7 cpm) of 125I-CNTFY and separated by SDS-PAGE showed a predominant 125I_CNTFY band and two much fainter bands at 45 kd and 14 kd, respectively (Fig 4a, lane  S) . During the first hour after i.v. injection the intensity of all three bands decreased, but no further radioactive band appeared that might result from potential degradation fragments of 125I_CNTFY (see Fig 4a) . By running the same serum samples on a nondenaturating polyacrylamide gel, it became apparent that after i.v. injection 125I_CNTFY is associated with two plasma proteins (Fig 4b) associated with the larger plasma protein migrates to the same position as 125I-CNTFY bound to human ar macroglobulin (a 2 M) (Fig 4c) .
Tissue Distribution of 125I_CNTFY after Intravenous Injection
During the first hour after i.v. injection of 0.1 fLg or 0.5 fLg of 125I_CNTFY, the highest tissue concentrations of 125I_CNTFY were detected in the liver. The levels of specific radioactivity in the liver declined during the following 6 hours to a similar low level as in the blood. During this time period, the levels of specific radioactivity in the skin increased gradually to levels that were higher than those in the liver (see Fig 3a) . Unexpect-. edly, spinal cord, brain, and skeletal muscle, tissues that are all known to express relatively high amounts of the CNTFRa mRNA [24, 25] , did not show any accumulation of radioactivity within 6 hours after i.v. injection of 125I_CNTFY (see Fig 3a) . Twelve hours after i.v. injection, levels of radioactivity in 10 mg of desanguinated skeletal muscle were less than 15% of those detectable in 10 fLl of blood. In the nervous system, relatively high levels of specific radioactivity were found only in the superior cervical ganglion (SCG) (500 cpm/lO mg of tissue) and sciatic nerve (200 cpm/IO mg of tissue), while the dorsal root ganglia contained less than 130 cpm/lO mg of tissue. AutOradiograms of spinal cord and brainstem did not show any accumulation of radioactivity (data not shown). Indeed, the levels of specific radioactivity in these tissues were less than 40 cpmllO mg (see Fig  3b) , corresponding to maximally 0.28 pg of intact 1251_ CNTFY per 10 mg of tissue, which is equivalent to not more than one trophic unit per gram of tissue.
Degradation of 125I_CNTFY by Liver Cells
To study the fate of 125I-CNTFY in the liver after i.v. injection, we separated liver homogenates by SDS-PAGE. Two major bands were detectable by autoradiography, an upper band, corresponding to 1251_ CNTFY, and a lower band at 14 kd, which is about 10 times less intensive and already detectable in the 1251-CNTFY preparation after radioiodination (Fig 5) . Between 1 and 3 hours after i.v. injection the intensity of the 1251-CNTFY band declined significantly (more Figure 4 .
than 80 x), whereas the total radioactivity in the liver was reduced only 1.7 x. Simultaneously, a band at 7 kd (presumably representing a proteolytic fragment of 1251-CNTFY) increased in intensity. At 6 hours after injection, most of the 125I_CNTFY appeared to be degraded, and the presumptive 7 -kd proteolytic fragment represented the dominant band. Consistent with this observation, only 21 % of the radioactivity in liver, taken 6 hours after i.v. injection of 125I_CNTFY and subsequently homogenized, could be precipitated in 20% TCA. Prior to injection, it was possible to precipitate 95% of the radioactivity from the 125I_CNTFY solution (Table) . We could not analyze skin homogenates by SDS-PAGE because their level of radioactivity was tOo low. However, 6 hours after i.v. injection of 125I_CNTFY, only 9% of the total radioactivity in skin could be precipitated (see Table) . These data indiate that the accumulated radioactivity in skin (see Fig   Trichloroacetic Acid 125I-CNTFY = 125I-labeled ciliary neurotrophic factor with three additional C-terminal tyrosine residues. 3a) can be attributed primarily to breakdown products of 125I-CNTFY. In contrast, in adrenal gland 74% of the tissue bound radioactivity could be precipitated by TCA 6 hours after i.v. injection of 125I-CNTFY (see Table) , suggesting that a major proportion of the radioactivity measured represents intact 125I_CNTFY.
Binding Sites oj1 25 I-CNTFY on Liver Cells Autoradiograms of liver sections 1 hour after i.v. injection of 0.1 f.Lg 0.94 X 10 7 cpm) of 125I_CNTFY, when most of the factOr was not expected to be degraded (see Fig 5) , showed an accumulation of silver grains over the cytoplasm and its compartments but not over the nuclei of rat liver cells (Fig 6) . This indicates that a significant proportion of the i.v. injected 125I_CNTFY is taken up into the hepatocytes.
To analyze whether the accumulation of i.v. injected 125I_CNTFY in liver cells results from the interaction with specific CNTF binding sites, we performed crosslinking studies to liver cells in situ with 125I_CNTFY (Fig 7) . To do this we injected 0.5 f.Lg (7 .1 x 10 7 cpm) of 125I_CNTFY into the tail vein and 5 minutes later, the cross-linking agent EDC into the portal vein of male Wistar rats 050-200 gm). At that time a high amount of 125I-CNTFY has already accumulated in the liver and, if bound to membrane proteins, would be expected to be cross-linked to them under the conditions used. Following cross-linking, SDS-PAGE of purified liver cell membrane proteins gave three bands of cross-linked proteins detectable by autoradiography at 99, 140, and 235 kd.
Biological Effects 0/ CNTF in the Liver after
Intravenous Injection
Recently, it has been shown that recombinant rat CNTF increases mRNA levels of acute-phase proteins in hepatOcytes in vitro (31, 35}. The accumulation of 125I-CNTFY in liver after i.v. injection (see Fig 3a) raises the question as to whether CNTF also induces acute-phase responses in vivo. To investigate this, the level of haptoglobin mRNA in the liver was determined by northern blot analysis after i.v. injection of CNTF (Fig 8) . Time course analysis showed that the level of haptOglobin mRN A in the liver reaches a maximum 8 hours after i.v. injection of 10 f.Lg of CNTF (Fig 8a) . The level of haptOglobin mRNA in CNTFtreated rats at this time was significantly greater by a factor of 2.3 (Student's t test, p = 0.005; n = 5) than in control rats injected with the same volume of buffer (Fig 8c) . Also 6 hours after i.v. injection of 10 f.Lg of CNTF, a more than 2 x higher haptoglobin mRNA level was detectable in comparison with control rats (Fig 8b) . Furthermore, the increase of haptOglobin mRNA level 6 hours after i.v. injection of CNTF was dose dependent (Fig 8d) . These results indicate that the effects of CNTF on hepatocytes are not confined ated, C-terminally modified recombinant rat CNTF e 25 I-CNTFY), whose biological activity in the chick ciliary neuron assay was indistinguishable from unmodified CNTF (see Fig 1) . Intravenously injected 125 1_ CNTFY shows biphasic clearance kinetics with a fast initial phase (see Fig 2) Corresponding experiments with unlabeled recombinant rat CNTF detected in serum by a rwo-site enzyme-linked immunosorbent assay [38} have shown similar results. Also in this experimental paradigm, the initial plasma half-life of CNTF was shorter than 10 minutes, suggesting that the rapid disappearance of radioactivity from the blood is not due to cleavage of the C-terminal 125I-tyrosine residues from the 125I-CNTFY molecule or to deiodination.
Analysis of the tissue distribution of 125I-CNTFY after i.v. injection revealed a correlation berween the fast elimination from the blood (see Fig 2) and the accumulation of 125I-CNTFY in the liver (see Fig 3a) . This situation is similar to that observed for the structurally related compound IL-6. Most of this factor (80%) is taken up by the liver 20 minutes after i.v. injection into rats [I7}. In contrast, for LIF, another structural analogue of CNTF, the fast elimination after i.v. injection into mice has been shown to be due to clearance by the kidneys [I9}. Our data suggest that bolus i.v. injection might be inadequate for clinical CNTF administration because it leads to poor bioavailability of CNTF for motoneurons. Moreover, these results might also have implications for subcutaneous injection of CNTF. Although long-term serum levels of proteins after subcutaneous injection might be higher than those after i.v. injection, as was shown for rhG-CSF [I8}, a significant proportion of subcutaneously injected CNTF would pass the liver once it has entered the bloodstream. Thus, other manners of CNTF application should be considered (see below).
That the elimination of i.v. injected 1251_CNTFY by the kidneys apparently does not play a major role in the clearance of this factor suggests that 125I_CNTFY might bind to plasma proteins. PAGE analysis under nondenaturating conditions shows the binding of 1251_ CNTFY to rwo distinct plasma proteins (see Fig 4b) . The smaller plasma protein seems to have a molecular mass of less than 100 kd.
Recently, soluble CNTFRa (sCNTFRa), which has a molecular mass of 68 kd, has been detected in human cerebrospinal fluid and blood plasma [39}' Thus, it is tempting to speculate that the smaller plasma protein shown in Figure 3b , binding most of the 125I_CNTFY, could be sCNTFRa. SDS-PAGE analysis under reduc~ ing conditions of the same blood samples revealed either that 125I_CNTFY is not degraded after i.v. injection in the blood, at least not during the first hour after injection (see Fig 4a) , or that its fragments are removed from the circulation immediately after degradation. In contrast, a radiolabeled 7 -kd polypeptide was detectable in liver extracts, which progressively increased in relative intensity compared with the 125I-CNTFY band during the first 6 hours, during which time the intensity as a positive control.
RNA markers is indicated in kilobases;
of the 1251-CNTFY band decreased (see Fig 5) . The 7 -kd polypeptide may be a proteolytic fragment of 1251_ CNTFY. Many proteins, including IL-6 and NGF have been shown to be protected from proteolysis after binding to a 2 M in the blood [40, 41J. Correspondingly, the larger plasma protein, which binds 125 1_ CNTFY (see Fig 4b) , might be a 2 M. In support of this hypothesis, we found that 1251_CNTFY, associated with the larger plasma protein, migrates to the same position as 1251-CNTFY bound to human a 2 M (see Fig 4c) . The accumulation of 1251_CNTFY in the liver after i.v. injection was surprising, as CNTFRa, the primary CNTF binding site on CNTF-responsive cells [42J, was not expected in high amounts in this organ according to the reported levels of CNTFRa mRN A [24, 25] . However, high amounts of cell membraneassociated CNTFRa might not be necessary for the accumulation of 125I_CNTFY in the liver, if one assumes that most of the i.v. injected CNTF becomes associated with sCNTFRa in the blood. The 125 1_ CNTFY I sCNTFRa complex might then bind in the liver to other subunits of the CNTF receptor complex associated with the cell membrane [39, 43J and present on liver cells (Fig 9 as a model of CNTF disposition after i.v. injection). Under these assumptions, the accumulation of CNTF in liver would require that these other subunits are highly expressed in cells of this organ.
The cell membrane-associated CNTF receptor complex has been suggested to be composed of at least three subunits, CNTFRa, gp130, and LIFR [3 [20-22, 39, 43, 44] . The glycoprotein gp130 has been shown to transduce the CNTF signal, most likely together with at least one other component, which might be the LIFR [3 [22, 39, 43 , 44J, and to be highly expressed by liver cells [25}. Therefore, binding of a 125I_CNTFYI sCNTFRa complex to gp 130 might mediate the accumulation of 1251-CNTFY in the liver. The model of the cell membrane-associated CNTF receptor complex is consistent with our results obtained by cross-linking of 125I-CNTFY to liver in situ (Fig 7) . Taking into account a molecular mass of 23 kd for 125I_CNTFY, we observed a cross-linked protein of 76 kd on liver cells, which is the expected size of the rat CNTFRa [24, 39J. It has been proposed that on primary rat hepatocytes, CNTF binds to the IL-6Ra [35J, which has a molecular mass of approximately 80 kd [32] . However, CNTF does not bind to the soluble IL-6Ra, and a hepatoma cell line lacking the IL-6Ra responds to CNTF [31] . Therefore, it is highly likely that 125I_CNTFY is crosslinked to rat liver cells (i.e., predominately hepatocytes) in situ to CNTFRa. Two other bands detectable after cross-linking of 125I-CNTFY to liver cells in situ showed relative molecular masses of about 140 kd and 235 kd (see Fig 7) . The molecular mass of gp130 expressed on a rat sympathoadrenal progenitor cell line has been reported to be 145 kd [25J, and for the ungly- cosylated human form of gp130, a molecular mass of lOl kd has been determined [45, 46] . Therefore, the cross-linked band of 140 kd could result from 125 1_ CNTFY bound to gp130 being tissue-specifically glycosylated to a lesser extent than in neuronal cells. The 235-kd band could represent 12SI_CNTFY cross-linked to the LIFR[3, as the molecular mass of the glycosylated form of the human placental LIFRI3 is 190 kd [47] . Thus, on liver cells, the initial steps of signal transduction following CNTF binding may be identical to those described for neuronal cell lines [44J and for an erythroleukemia cell line [43] .
Six hours after i.v. injection of 125I-CNTFY, radioactivity accumulated in the hairy skin, the tissue with the highest specific radioactivity at this time point (Fig 3a) . This is strikingly similar to the tissue distribution of 125I_rhIL_6 after i.v. injection in the rat: At 5 hours, the radioactivity attributable to 1251_rhIL_6 in liver had declined significantly and high levels were found in skin, which radioactivity was suggested to be degradation products of 1251_rhIL_6 generated by fibroblasts [48] . In contrast, our results indicate that the degradation of 1251_CNTFY has already taken place in the liver (see Fig 5) , and that the radioactivity accumulated in the fat cells of the hairy skin (data not shown) does not represent intact 125I_CNTFY, but breakdown products (see Table) .
Our data suggest that 1251_CNTFY does not accumulate in skeletal muscle after systemic administration (see Fig 3a) . Even 12 hours after injection, the specific radioactivity detectable in skeletal muscle was low~r than that of either liver, adrenal gland, or the SCG (see Fig 3b) . This seems to be at odds with the reported high abundance of CNTFRa mRNA in skeletal muscle [24, 25] . Recently, it was suggested that, after nerve injury, a significant proportion of the CNTFRa produced in skeletal muscle is released into the circulation [39] . If this also happens in unlesioned animals, i.v. injected CNTF might bind to soluble and not cell membrane-associated CNTFRa in skeletal muscle. Preferential accumulation of 1251-CNTFY/sCNTFRa complex in the liver rather than in skeletal muscle may thus be due to a relatively high expression of gp 130 protein on the surface of liver cells, to which the 125 1_ CNTFY/sCNTFRa complex might bind.
A side effect of CNTF after systemic application is the increase of haptoglobin gene expression in the liver (see Fig 8) . Haptoglobin is an acute-phase protein [49}, whose gene expression is increased by CNTF in a human hepatoma cell line [31}. Stimulation of acutephase responses by recombinant human cytokines were also observed in vitro with primary hepatocytes and hepatoma cell lines for IL-6 [SO}, LIF [51}, and oncostatin M [52}, and in vivo for IL-6 [53, 54] . Therefore, one might assume that there are similar signaling pathways for these effects in hepatic cells. Indeed, the receptors of these cytokines are members of a hematopoietic cytokine receptor family [20, 55}, which use gp130 for signal transduction [43, 45, 56 , 57}. Recently, gp130 was also described as being involved in CNTF signal transduction in neuronal cells [43, 44}, as well as in an erythroleukemia cell line [43] . Our data concerning the cross-linking of 1251_CNTFY to membrane proteins of liver cells in situ (see Fig 7) suggest that gp130 and LIFR~ are involved in the initial CNTF signal transduction for the induction of acute-phase response in hepatocytes. Further experiments are required to determine whether CNTF and LIF, which are believed to use the same initial signal transduction pathways (for reviews, see [21, 22}) , induce identical patterns of acute-phase proteins in liver.
Taken together, our results indicate that systemic injection of CNTF might not lead to optimal availability to motoneurons, the target cells for the clinical use of CNTF in motoneuron disease. Most i.v. injected CNTF is taken up (see Fig 3a) and degraded (Fig 4) by the liver. Not more than one trophic unit of 125 1_ CNTFY per gram of tissue could be detected in the spinal cord 12 hours after i.v. injection of 0.5 f.Lg of 12SI_CNTFY. Even under optimal diffusion conditions such as in cell culture, one trophic unit of CNTF would elicit only half-maximal response on neuronal survival. As CNTF is a protein of 200 amino acids, low diffusion within the extracellular space is expected to prevent the majority of CNTF from binding to its specific neuronal receptors. Correspondingly, previous experiments have shown that about 500 trophic units per milliliter of blood are necessary to improve motor function in pmn mice [8, 38} , an animal model of human motoneuron disease.
Even if positive results with systematically administered CNTF were obtained in ALS patients, our results indicate that optimization of CNTF delivery will be necessary to obtain maximal therapeutic benefit. One way to improve the bioavailability of compounds to the central nervous system (CNS) and nerve roots is intrathecal injection [58, 59] , Alternatively, it might be necessary to use gene therapeutic approaches [60, 61} to provide increased concentrations of CNTF within the CNS at its sites of action, i.e., motoneurons in the spinal cord and regions within the CNS containing upper motoneurons.
In addition, side effects of systemically administered CNTF on hepatocytes might further limit this therapeutical approach. From our study, we would predict the induction of acute-phase proteins as a side effect of CNTF in patients treated with pharmacological doses of this factor. However, quantitative toxicological data relevant to the use of CNTF in patients can only be obtained from clinical trials.
